Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

NCT02452554 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT02452554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02452554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
October 12, 2015
Completion date
September 30, 2021
Enrollment
62 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

pleuropulmonary blastoma, recurrent malignant peripheral nerve sheath tumor, recurrent neuroblastoma, recurrent rhabdomyosarcoma, recurrent synovial sarcoma, wilms tumor